Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials-Reference-Cited by-同舟云学术

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Published:2024-04-29 Issue:3 Volume:11 Page:737-753
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Burmester Gerd R.^ORCID,Stigler Jayne,Rubbert-Roth Andrea,Tanaka Yoshiya,Azevedo Valderilio F.,Coombs Derek,Lagunes Ivan,Lippe Ralph,Wung Peter,Gensler Lianne S.

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40744-024-00671-4.pdf

Reference30 articles.

1. Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol. 2012;26:135–45.

2. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896–907.

3. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58:i43–54.

4. Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–45.

5. Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18:253–61.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29